H

Hospital Cardiologica Aguascalientes | Instituto de Investigación - Departamento de Cardiología

Research site
(Unclaimed)
Location
Republica De Ecuador 200, Aguascalientes, Aguascalientes, Mexico
Site insights

Top conditions

COVID-19 (4 trials)

Cardiovascular Diseases (3 trials)

Heart Failure (3 trials)

Gastroparesis (3 trials)

Diabetes Mellitus (3 trials)

Top treatments

Relamorelin
Empagliflozin
Dabigatran
LY3298176
Ritonavir
BELVIQ
Milvexian
Lorcaserin HCl
Finerenone
Bococizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

4 of 24
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiov...

Active, not recruiting
Heart Failure
Other: Placebo
Drug: Finerenone (BAY94-8862)

Trial sponsors

Boehringer Ingelheim logo

Boehringer Ingelheim (10 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems